About this document
Lumateperone Drug Information Summary by ehsaniali2 is a document available to read on EtoBox.
Lumateperone, marketed as Caplyta, is a second-generation atypical antipsychotic indicated for bipolar major depression and schizophrenia, with a recommended dosage of 42 mg once daily. It carries a US boxed warning for increased mortality in elderly patients with dementia-related psychosis and a risk of suicidal thoughts in younger patients. Common adverse reactions include drowsiness and sedation, with significant concerns regarding metabolic syndrome, extrapyramidal symptoms, and hematologic abnormalitie
- Author
- ehsaniali2
- Language
- EN